Open-label, Single-dose, Parallel-group Study to Compare the PKs of Iloperidone in Subjects With Mild or Moderate Hepatic Impairment With That in Matched Healthy Control Subjects
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Iloperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 21 Aug 2012 New trial record